CEO COMMENTS
Kristina Torfgård comments Q2 report 2025
“I have now been CEO of IRLAB for just over a year – a period marked by intensive work, progress, collaborations, and important decisions, which we are now building on with full force. The positive development we saw at the beginning of the year has continued during the second quarter, and I am particularly pleased with the progress we have made in our three most advanced projects. Our portfolio of drug candidates is strong, with several now ready for or approaching out-licensing and partnerships. Thanks to the capital raised from the rights issue carried out this past summer, we can now continue to drive the prioritized activities aimed at establishing partnerships and licensing agreements for our candidates and thereby realizing the commercial value of the projects.
Key Milestones During the Quarter and after:
- The application to start a Phase Ib study with IRL757 in patients with Parkinson’s and apathy is ready to submit. Our strategic partnerships with MSRD/Otsuka and the Michael J. Fox Foundation are key drivers in the development of IRL757.
- The recently granted patent for mesdopetam in the US further strengthens the already robust patent and exclusivity protection with the potential for market exclusivity well into the 2040s.
- New study data for pirepemat confirm the potential for continued development, and an additional study is planned to optimize dosing.
Together, these advances demonstrate that we are well on our way to realizing our vision and creating value for patients, partners and shareholders.”
LATEST REPORTS
IRLAB progresses fully funded IRL757 study in Parkinson’s Disease in partnership with MSRD
Gothenburg, Sweden, October 2, 2025 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that its collaborator, – the McQuade Center for Strategic Research and Development, LLC (MSRD) – has issued a payment of USD 4 million to further advance the drug candidate IRL757 into a clinical safety, tolerability and Signal Finding Study in patients with Parkinson’s disease who experience apathy. The first patients are expected to be enrolled before the end of 2025.
Read More >
Presentation by Kristina Torfgård, CEO, at Aktiespararna
Presentation by Kristina Torfgård, CEO, at Aktiespararna (in Swedish), held June 10, 2025.
Read More >FINANCIAL CALENDAR
NEXT
October 29 2025
Interim Report January – September 2025